Golimumab effectively reduces the signs and symptoms of active rheumatoid arthritis in patients who have previously failed treatment with at least one tumor necrosis factor inhibitor. Is it now time to develop strategies for sequential drug administration?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Smolen, J. S. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374, 210–221 (2009).
Yazici, Y. Treatment of rheumatoid arthritis: we are getting there. Lancet 374, 178–180 (2009).
Scott, D. L. & Cope, A. New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extended choice? Ann. Rheum. Dis. 68, 767–769 (2009).
Tubach, F. et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registery. Arthritis Rheum. 60, 1884–1894 (2009).
Felson, D. T. Whither the ACR20? J. Rheumatol. 31, 835–837 (2004).
Chung, C. P. et al. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. Ann. Rheum. Dis. 65, 1602–1607 (2006).
Bombardieri, S. et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 46, 1191–1199 (2007).
Hyrich, K. L. et al. Outcomes after switching from one anti-tumor necrosis factor α agent to a second tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 56, 13–20 (2007).
Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793–2806 (2006).
Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353, 1114–1123 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C. Deighton has been involved in speakers bureaus (honoraria) for and received grant/research support from Wyeth and Abbott, and has received grant/research support from Schering-Plough and Roche.
Rights and permissions
About this article
Cite this article
Deighton, C. What should we do after the failure of a first anti-TNF?. Nat Rev Rheumatol 5, 596–597 (2009). https://doi.org/10.1038/nrrheum.2009.212
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.212
